menu
Macular Degeneration Treatment Market Size, Share, Industry Growth, Trends, Analysis, Demand and Forecast by 2027
Macular Degeneration Treatment Market Size, Share, Industry Growth, Trends, Analysis, Demand and Forecast by 2027
The global macular degeneration treatment market reached a value of US$ 8.33 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 12.5 Billion by 2027 exhibiting a CAGR of 6.70% during 2022-2027.

Macular degeneration, also known as age-related macular degeneration (AMD), refers to a neurodegenerative ocular disorder that affects the macula part of the eye. It is characterized by blind spots in the central area of vision, inability to see in low light conditions, visual distortions, etc. Macular degeneration occurs when the capillaries around the fovea dilate and leak. Some widely utilized therapeutic techniques for macular degeneration treatment include anti-angiogenic drugs, photodynamic laser therapies, transitional lenses, contact lenses, etc. The laser therapy process consists of inserting specialized contact lenses into the affected area of the eye, which are sealed with the blood vessels. Macular degeneration treatment assists in improving vision and reducing the risks of developing chronic blindness.

Report Metric
Historical: 2016-2021
Base Year: 2021
Forecast Year: 2022-2027

According to the latest report by IMARC Group, titled "Global Macular Degeneration Treatment Market Growth, Size, Share, Industry Trends, Opportunity and Forecast 2022-2027", The global macular degeneration treatment market reached a value of US$ 8.33 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 12.5 Billion by 2027 exhibiting a CAGR of 6.70% during 2022-2027.

Macular Degeneration Treatment Market Trends and Drivers:

The growing incidences of ocular disorder, particularly among the geriatric population, are primarily driving the macular degeneration treatment market across the globe. Besides this, the rising usage of smartphones, laptops, and television is leading to prolonged and excessive screen time, which, in turn, is also propelling the market growth.

Furthermore, the introduction of retinal gene therapies that involve the injection of adeno-associated virus into the body for preventing the formation of abnormal blood vessels is acting as another significant growth-inducing factor. In line with this, significant improvements in the healthcare infrastructures are also positively influencing the global market.

Additionally, the increasing investments in R&D activities aimed at developing innovative and effective drugs to treat ophthalmological ailments are projected to fuel the macular degeneration treatment market over the forecasted period.

Get a PDF Sample for more detailed market insights: https://www.imarcgroup.com/macular-degeneration-treatment-market/requestsample

Note: We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.

Global Macular Degeneration Treatment Market 2022-2027 Analysis and Segmentation:

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

Aerie Pharmaceuticals Inc.

Bausch Health Companies Inc.

Bayer AG

F. Hoffmann-La Roche Ltd

Iveric Bio Inc.

Novartis AG

Panoptica

Pfizer Inc.

Phio Pharmaceuticals

Regeneron Pharmaceuticals Inc.

Regenxbio Inc.

Santen Pharmaceutical Co. Ltd

The report has segmented the market on the basis of region, type, stage of disease, route of administration and end user.

Breakup by Type:

  • Dry Age-related Macular Degeneration
  • Wet Age-related Macular Degeneration

Breakup by Stage of Disease:

  • Early Stage
  • Intermediate Stage
  • Late Stage

Breakup by Route of Administration:

  • Intravenous Route
  • Intravitreal Route

Breakup by End User:

  • Hospitals
  • Ambulatory Surgical Center
  • Others

Breakup by Region:

  • North America: (United States, Canada)
  • Asia Pacific: (China, Japan,India, South Korea, Australia, Indonesia, Others)
  • Europe: (Germany, France,United Kingdom, Italy, Spain, Russia, Others)
  • Latin America: (Brazil, Mexico, Others)
  • Middle East and Africa

Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/macular-degeneration-treatment-market

If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.

Key highlights of the report:

  • Market Performance (2016-2021)
  • Market Outlook (2022- 2027)
  • Porter’s Five Forces Analysis
  • Market Drivers and Success Factors
  • SWOT Analysis
  • Value Chain
  • Comprehensive Mapping of the Competitive Landscape

If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Services Private Limited.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800